Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors (Journal article)

Stoyianni, A./ Pentheroudakis, G./ Pavlidis, N.


INTRODUCTION: Neuroendocrine carcinomas of unknown primary (NCUP) represent a specific subset with relatively favorable prognosis. Data on biology, management and outcome of NCUP patients have not been systematically reviewed neither compared to those of neuroendocrine tumors of known primary. PATIENTS AND METHODS: We systematically reviewed all publications studying neuroendocrine CUP patients and presented a single center retrospective patient series. In addition, we analyzed and specified the similarities and/or differences between NCUP and other neuroendocrine malignancies. RESULTS: Five hundred patients with NCUP constituted a heterogeneous cohort in terms of histology, grade, anatomic site and tumor biology in published series and were managed mostly with platinum-based regimens. Among 294 patients with available outcome data, a median survival of 15.5 months (range 11.6-40) was observed. Comparative analysis with neuroendocrine solid tumors (NET) revealed that poorly-differentiated NCUP share an aggressive natural history and a dismal prognosis similar to high grade pulmonary and extrapulmonary neuroendocrine carcinomas (Large Cell Neuroendocrine bronchial Carcinomas, LCNEC and poorly differentiated gastroenteropancreatic tumors, GEP-NET). Well differentiated NCUP reveal a more indolent course with a survival range resembling that of typical and atypical pulmonary carcinoids, well differentiated gastrointestinal NETs and limited small cell lung carcinomas. CONCLUSION: No evidence for distinct biology or outcome of NCUP patients emerged when histological grade was matched for known primary NETs. The high heterogeneity of the NCUP subgroup limits the potential for identification of reliable prognosticators and hinders development of novel targeted therapies.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Carcinoma, Neuroendocrine/*mortality/*pathology/therapy,Combined Modality Therapy,Disease-Free Survival,Female,Humans,Male,Neoplasm Invasiveness/pathology,Neoplasm Staging,Neoplasms, Unknown Primary/*mortality/*pathology/therapy,Prognosis,Risk Assessment,Survival Analysis,Treatment Outcome
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/19785
ISSN: 1532-1967
Link: http://www.ncbi.nlm.nih.gov/pubmed/21481536
http://ac.els-cdn.com/S0305737211000429/1-s2.0-S0305737211000429-main.pdf?_tid=31d024ffe75bd670e4a4a883cda09eea&acdnat=1333955164_0d054e2475f3e0a941d82f13bbdefc95
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Stoyianni-2011-Neuroendocrine carci.pdf204.32 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/19785
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.